vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Howard Hughes Holdings Inc. (HHH). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $235.9M, roughly 1.2× Howard Hughes Holdings Inc.). Howard Hughes Holdings Inc. runs the higher net margin — 3.4% vs -45.7%, a 49.1% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 18.4%). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -13.8%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Howard Hughes Holdings Inc., formerly the Howard Hughes Corporation, is a real estate development and management company based in The Woodlands, Texas. It was formed in 2010 as a spin-off from General Growth Properties (GGP). Most of its holdings are focused on several master-planned communities. It took its name from the original Howard Hughes Corporation, which had developed the planned community of Summerlin, Nevada, and later became a subsidiary of GGP.
GH vs HHH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $235.9M |
| Net Profit | $-128.5M | $8.1M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 121.6% |
| Net Margin | -45.7% | 3.4% |
| Revenue YoY | 39.4% | 18.4% |
| Net Profit YoY | -15.8% | -25.6% |
| EPS (diluted) | $-1.01 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $235.9M | ||
| Q4 25 | $281.3M | $624.4M | ||
| Q3 25 | $265.2M | $390.2M | ||
| Q2 25 | $232.1M | $260.9M | ||
| Q1 25 | $203.5M | $199.3M | ||
| Q4 24 | $201.8M | $935.0M | ||
| Q3 24 | $191.5M | $327.1M | ||
| Q2 24 | $177.2M | $317.4M |
| Q1 26 | — | $8.1M | ||
| Q4 25 | $-128.5M | $6.0M | ||
| Q3 25 | $-92.7M | $119.5M | ||
| Q2 25 | $-99.9M | $-12.1M | ||
| Q1 25 | $-95.2M | $10.5M | ||
| Q4 24 | $-111.0M | $156.3M | ||
| Q3 24 | $-107.8M | $72.8M | ||
| Q2 24 | $-102.6M | $21.1M |
| Q1 26 | — | — | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — |
| Q1 26 | — | 121.6% | ||
| Q4 25 | -43.0% | 4.2% | ||
| Q3 25 | -37.3% | 48.6% | ||
| Q2 25 | -45.9% | 26.0% | ||
| Q1 25 | -54.6% | 24.0% | ||
| Q4 24 | -62.4% | 33.5% | ||
| Q3 24 | -61.3% | 60.6% | ||
| Q2 24 | -56.8% | 20.4% |
| Q1 26 | — | 3.4% | ||
| Q4 25 | -45.7% | 1.0% | ||
| Q3 25 | -35.0% | 30.6% | ||
| Q2 25 | -43.0% | -4.7% | ||
| Q1 25 | -46.8% | 5.3% | ||
| Q4 24 | -55.0% | 16.7% | ||
| Q3 24 | -56.3% | 22.2% | ||
| Q2 24 | -57.9% | 6.6% |
| Q1 26 | — | $0.14 | ||
| Q4 25 | $-1.01 | $0.20 | ||
| Q3 25 | $-0.74 | $2.02 | ||
| Q2 25 | $-0.80 | $-0.22 | ||
| Q1 25 | $-0.77 | $0.21 | ||
| Q4 24 | $-0.90 | $3.14 | ||
| Q3 24 | $-0.88 | $1.46 | ||
| Q2 24 | $-0.84 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $1.8B |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $3.8B |
| Total Assets | $2.0B | $11.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.8B | ||
| Q4 25 | $378.2M | $1.5B | ||
| Q3 25 | $580.0M | $1.5B | ||
| Q2 25 | $629.1M | $1.4B | ||
| Q1 25 | $698.6M | $493.7M | ||
| Q4 24 | $525.5M | $596.1M | ||
| Q3 24 | $585.0M | $400.7M | ||
| Q2 24 | $933.7M | $436.8M |
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | $5.1B | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | $5.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $3.8B | ||
| Q4 25 | $-99.3M | $3.8B | ||
| Q3 25 | $-354.5M | $3.8B | ||
| Q2 25 | $-305.5M | $3.6B | ||
| Q1 25 | $-250.8M | $2.8B | ||
| Q4 24 | $-139.6M | $2.8B | ||
| Q3 24 | $-60.1M | $2.6B | ||
| Q2 24 | $-1.6M | $3.0B |
| Q1 26 | — | $11.2B | ||
| Q4 25 | $2.0B | $10.6B | ||
| Q3 25 | $1.3B | $10.7B | ||
| Q2 25 | $1.3B | $10.3B | ||
| Q1 25 | $1.3B | $9.3B | ||
| Q4 24 | $1.5B | $9.2B | ||
| Q3 24 | $1.5B | $9.4B | ||
| Q2 24 | $1.6B | $9.9B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.35× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.85× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | — |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-26.4M | $360.3M | ||
| Q3 25 | $-35.4M | $149.8M | ||
| Q2 25 | $-60.3M | $177.3M | ||
| Q1 25 | $-62.7M | $-224.9M | ||
| Q4 24 | $-64.5M | $337.1M | ||
| Q3 24 | $-51.1M | $248.3M | ||
| Q2 24 | $-94.0M | $-17.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-54.2M | $348.6M | ||
| Q3 25 | $-45.8M | $137.7M | ||
| Q2 25 | $-65.9M | $169.7M | ||
| Q1 25 | $-67.1M | $-238.4M | ||
| Q4 24 | $-83.4M | $317.1M | ||
| Q3 24 | $-55.3M | $238.7M | ||
| Q2 24 | $-99.1M | $-25.1M |
| Q1 26 | — | — | ||
| Q4 25 | -19.3% | 55.8% | ||
| Q3 25 | -17.3% | 35.3% | ||
| Q2 25 | -28.4% | 65.1% | ||
| Q1 25 | -33.0% | -119.6% | ||
| Q4 24 | -41.3% | 33.9% | ||
| Q3 24 | -28.9% | 73.0% | ||
| Q2 24 | -55.9% | -7.9% |
| Q1 26 | — | — | ||
| Q4 25 | 9.9% | 1.9% | ||
| Q3 25 | 3.9% | 3.1% | ||
| Q2 25 | 2.4% | 2.9% | ||
| Q1 25 | 2.2% | 6.8% | ||
| Q4 24 | 9.4% | 2.1% | ||
| Q3 24 | 2.2% | 2.9% | ||
| Q2 24 | 2.9% | 2.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 60.04× | ||
| Q3 25 | — | 1.25× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -21.35× | ||
| Q4 24 | — | 2.16× | ||
| Q3 24 | — | 3.41× | ||
| Q2 24 | — | -0.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
HHH
| Rental revenue | $113.5M | 48% |
| Master Planned Communities land sales | $99.6M | 42% |
| Other revenues | $11.0M | 5% |
| Builder price participation | $8.7M | 4% |
| Condominium rights and unit sales | $3.1M | 1% |
